| PASG |
Passage BIO, Inc. |
Common Stock, par value $0.0001 per share |
20% |
$243,245 |
-$3,366,967 |
623,704 |
-93% |
LYNX1 CAPITAL MANAGEMENT LP |
30 Sep 2025 |
| GHRS |
GH Research PLC |
Ordinary Shares, nominal value $0.025 per share |
17% |
$164,840,148 |
+$28,597,314 |
10,406,575 |
+21% |
Lynx1 Capital Management LP |
31 Dec 2025 |
| NEUP |
Neuphoria Therapeutics Inc. |
Common Stock, par value $0.00001 per share |
16% |
$3,877,703 |
|
875,328 |
0% |
Lynx1 Capital Management LP |
26 Dec 2025 |
| TCRX |
TScan Therapeutics, Inc. |
Voting Common Stock, par value $0.0001 per share |
15% |
$11,393,153 |
+$3,625,000 |
7,857,347 |
+47% |
Lynx1 Capital Management LP |
30 Jun 2025 |
| CGEM |
Cullinan Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
14% |
$50,697,778 |
+$24,599,905 |
8,549,084 |
+94% |
Lynx1 Capital Management LP |
08 Oct 2025 |
| KRRO |
Korro Bio, Inc. |
Common Stock, par value $0.001 per share |
7.8% |
$5,531,593 |
|
733,633 |
|
Lynx1 Capital Management LP |
23 Dec 2025 |
| CCCC |
C4 Therapeutics, Inc. |
Common Stock, $0.0001 par value per share |
7.3% |
$13,557,434 |
|
7,098,133 |
|
Lynx1 Capital Management LP |
31 Dec 2025 |
| ALLO |
Allogene Therapeutics, Inc. |
Common Stock, par value $0.001 per share |
5.2% |
$16,747,073 |
|
10,874,723 |
|
Lynx1 Capital Management LP |
31 Dec 2024 |
| DTIL |
PRECISION BIOSCIENCES INC |
Common Stock, par value $0.000005 per share |
4.1% |
$4,084,982 |
-$200,087 |
993,913 |
-4.7% |
Lynx1 Capital Management LP |
31 Dec 2025 |
| IBIO |
iBio, Inc. |
Common Stock, $0.001 par value per share |
0% |
$0 |
|
0 |
|
Lynx1 Capital Management LP |
31 Dec 2025 |